Scientists have developed a method that exploits the multitargeted nature of a chemical inhibitor to pinpoint vulnerabilities within cancer cells.

When signalling pathways within cells are triggered, proteins activate through a chain reaction, like a row of tumbling dominoes, until the final protein influences some cellular function.

In some tumours, multiple signalling pathways drive cell growth and survival.

This redundancy means that if one pathway ceases activity, another could continue driving cancerous behaviour.

Thus, drugs with the ability to shut down multiple pathways at the same time could be advantageous.

Many cancer drugs, including some clinically approved kinase inhibitors, were originally designed to block the function of specific molecules but it is now known that their benefits might not always stem from the inhibition of single targets.

"Many of these covalent inhibitors are in fact some degree polypharmacological in their action and they can target multiple things," said Nathanael Gray, a professor of biological chemistry and molecular pharmacology at Harvard Medical School and the Dana Farber Cancer Institute in Boston, Massachusetts. "They're advertised as working through one target, but people in the field know that several other targets contribute."

In a study published in the Journal of Biological Chemistry, a team researchers led by Gray identified key molecules that support the survival of a specific type of lung cancer cells.

By analysing the response of these cells to a cancer-killing kinase inhibitor with numerous targets, they were able to show that the anti-cancer effects were likely elicited by simultaneous inhibition of specific molecules in two signalling pathways.

This approach to drug-target discovery could be useful for designing drugs that selectively attack multiple proteins, which is beneficial for managing certain tumours.

Although kinase inhibitors hit multiple targets, most were not designed to do so, which means they might bind to molecules unnecessarily and lead to adverse effects.

Because it has been unclear which combinations of targets would have the most desirable effects, it has been challenging for researchers to purposefully design multitargeted drugs for cancer, Gray said.

To allow better drug design, Gray sought to discover which of the many buttons pushed by these inhibitors enables their anti-cancer effects.

In a study to be published later this year, Gray and his lab investigated the kinase inhibitor SM1-71 and, using a suite of chemical proteomic and cellular techniques, showed that it actually binds to dozens of kinases, some of which are involved in critical signalling pathways that support cell survival and growth.

"It was sort of like a stick of dynamite and really could hit a lot of different targets," Gray said.

The researchers exposed different types of cancer cells to SM1-71 and found that the drug was highly toxic to a specific line of lung cancer cells with mutated KRAS protein, which is common in some tumours and leads to constant activation of signalling pathways that drive cell growth.

"The ability of the inhibitor to kill these cells in spite of this mutation suggested that targets in several pathways were being hit", Gray added.

To find which inhibitory interactions were curbing cancer activity, the researchers first identified which kinases in their previously generated list of SM1-71 targets were known to be key signalling proteins for cell growth and survival.

They then narrowed down these candidates with Western blotting, which showed if any of these proteins from the cancer cells were actually being inhibited and saw that proteins in two critical pathways were indeed being blocked.

The authors then applied various kinase inhibitors used in research and the clinic to see if specifically inhibiting any combination of these proteins would replicate the effects that SM1-71 had on the cancer cells.

"In the end, inhibiting MEK1/2 and IGF1R/INSR proteins at the same time demonstrated similar effects, suggesting these are crucial targets in this lung cancer line", Gray stated. "SM1-71 itself would not likely be viable in humans because it binds to too many proteins and can lead to collateral damage. But uncovering its most important targets within specific pathways could aid the design of future drugs that can multiple signalling pathways in tumours."

"The next step would be to try to preserve the efficacy driving targets while getting rid of targets that may be contributing to the toxicology," Gray concluded.

Source: American Society for Biochemistry and Molecular Biology